Essential Fatty Acid (EFA) Nutrition 5-Year-Olds Follow-Up Study
Launched by UNIVERSITY OF BRITISH COLUMBIA · Apr 27, 2010
Trial Information
Current as of June 14, 2025
Completed
Keywords
ClinConnect Summary
This research is a prospective follow-up on an existing cohort of women and their children to determine whether dietary intakes of docosahexaenoic acid (DHA) during pregnancy have effects lasting into early childhood. The purpose of this study is to assess the relationship between maternal DHA status in gestation, which is known, and the child 's own diet and relevant genetic variables on the child's neural, cognitive and behavioral development. Hypotheses: 1. maternal DHA status in gestation has a lasting effect on infant development evident when assessed in early childhood 2. Children wit...
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Mothers who participated in study (REB # C03-0242 and C\&W W03-0084)
- • who have already provided written consent for re-contact to participate with their 5 year old child.
- Exclusion Criteria:
- • Mothers who did not participate in the previous study "N-3 fatty acid requirements for human development"
- • Mothers who have not provided written consent for re-contact.
About University Of British Columbia
The University of British Columbia (UBC) is a leading research institution located in Vancouver, Canada, renowned for its commitment to advancing health sciences through innovative research and education. As a prominent clinical trial sponsor, UBC leverages its interdisciplinary expertise and state-of-the-art facilities to conduct rigorous clinical studies aimed at improving patient outcomes across various medical fields. The university fosters collaborations with healthcare professionals, industry partners, and community stakeholders to translate research findings into practical applications, thereby contributing to the global advancement of medicine and public health.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Vancouver, British Columbia, Canada
Patients applied
Trial Officials
Sheila M. Innis, Dr.
Principal Investigator
University of British Columbia
Tim Oberlander, MD
Study Director
University of British Columbia
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials